李瑛, 李磊, 孟红旭, 王奥奥, 王紫艳, 张国瑗, 史跃, 马彦雷, 林力, 刘建勋. 基于血小板蛋白质组学探讨小型猪痰瘀互结证冠心病的发病机制J. 药学学报, 2023, 58(7): 1904-1912. DOI: 10.16438/j.0513-4870.2022-1294
引用本文: 李瑛, 李磊, 孟红旭, 王奥奥, 王紫艳, 张国瑗, 史跃, 马彦雷, 林力, 刘建勋. 基于血小板蛋白质组学探讨小型猪痰瘀互结证冠心病的发病机制J. 药学学报, 2023, 58(7): 1904-1912. DOI: 10.16438/j.0513-4870.2022-1294
LI Ying, LI Lei, MENG Hong-xu, WANG Ao-ao, WANG Zi-yan, ZHANG Guo-yuan, SHI Yue, MA Yan-lei, LIN Li, LIU Jian-xun. The coronary heart disease of phlegm-stasis cementation syndrome in mini-swine based on platelet proteomicsJ. Acta Pharmaceutica Sinica, 2023, 58(7): 1904-1912. DOI: 10.16438/j.0513-4870.2022-1294
Citation: LI Ying, LI Lei, MENG Hong-xu, WANG Ao-ao, WANG Zi-yan, ZHANG Guo-yuan, SHI Yue, MA Yan-lei, LIN Li, LIU Jian-xun. The coronary heart disease of phlegm-stasis cementation syndrome in mini-swine based on platelet proteomicsJ. Acta Pharmaceutica Sinica, 2023, 58(7): 1904-1912. DOI: 10.16438/j.0513-4870.2022-1294

基于血小板蛋白质组学探讨小型猪痰瘀互结证冠心病的发病机制

The coronary heart disease of phlegm-stasis cementation syndrome in mini-swine based on platelet proteomics

  • 摘要: 基于血小板蛋白质组学技术研究分析痰瘀互结证冠心病的关键调节蛋白和发病机制。基于前期实验室研究基础复制小型猪痰瘀互结证冠心病动物模型, 通过血脂及心肌组织特征变化进行模型判断, 进一步通过定量蛋白质组学技术对血小板蛋白进行研究, 筛选得到差异蛋白, 并通过生物信息学分析痰瘀互结证冠心病的关键调节蛋白及生物途径。动物实验已获得中国中医科学院西苑医院伦理委员会的批准(伦理号2021XLC037)。研究结果表明, 模型组在造模10周后总胆固醇(total cholesterol, TC)、低密度脂蛋白(low-density lipoprotein cholesterol, LDL-C)、极低密度脂蛋白(very low density lipoprotein, VLDL-C)、甘油三酯(triglyceride, TG) 及肌酸激酶(creatine kinase, CK) 和肌酸激酶同工酶(creatine kinase-MB, CK-MB) 水平均明显升高, 反映模型组出现血脂升高、凝血功能异常及心肌缺血等病理变化特征。此外, 相比于假手术组, 模型组血小板中有26个上调蛋白, 8个下调蛋白。生物信息学分析发现, 差异蛋白主要参与糖酵解/糖异生、丙酮酸代谢、脂质与动脉粥样硬化、Ras蛋白信号转导等。其中乳酸脱氢酶B (lactate dehydrogenase B, LDHB)、乙醇脱氢酶5 (alcohol dehydrogenase 5, ADH5)、神经母细胞瘤病毒癌基因RAS同系物(neuroblastoma ratsarcoma viral oncogene homolog, NRAS) 和Kirsten大鼠肉瘤病毒癌基因同源物(Kirsten ratsarcoma viral oncogene homolog, KRAS) 与其他蛋白质相互作用时起到中枢作用, 并同时参与多条作用通路。结果显示, LDHB、ADH5、NRAS和KRAS可能是痰瘀互结证冠心病中的标志性蛋白, 通过调节糖酵解/糖异生、丙酮酸代谢、脂质与动脉粥样硬化、Ras蛋白信号转导等生物过程, 从而导致痰瘀互结证冠心病的发生。

     

    Abstract: Based on the technology of platelet proteomics, the key regulatory proteins and pathogenesis of coronary heart disease with phlegm and blood stasis syndrome were explored and analyzed. Based on the previous laboratory research, the model of coronary heart disease in mini-swine with phlegm-stasis cementation syndrome was duplicated. The model was judged by the changes in blood lipid and myocardial tissue characteristics. Furthermore, the platelet proteins were studied by quantitative proteomics, and the differentially expressed proteins were screened. The critical regulatory proteins and biological pathways of coronary heart disease with phlegm-stasis cementation syndrome were analyzed by bioinformatics. After ten weeks of modeling, the levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), very low density lipoprotein (VLDL-C), triglyceride (TG), creatine kinase (CK) and creatine kinase-MB (CK-MB) in the model group were significantly increased, reflecting the pathological changes such as increased blood lipid, abnormal coagulation function and myocardial ischemia in the model group. In addition, compared with the sham group, there were 26 up-regulated proteins and 8 down-regulated proteins in the platelets of the model group. Combined with bioinformatics analysis, it was found that differential proteins mainly involved in glycolysis/gluconeogenesis, pyruvate metabolism, lipid and atherosclerosis, Ras protein signal transduction. Among them, lactate dehydrogenase B (LDHB), alcohol dehydrogenase 5 (ADH5), neuroblastoma ratsarcoma viral oncogene homolog (NRAS) and Kirsten ratsarcoma viral oncogene homolog (KRAS) play a central role when interacting with other proteins and simultaneously participate in multiple action pathways. The results showed that LDHB, ADH5, NRAS, and KRAS may be the marker proteins in CHD with phlegm-stasis cementation syndrome by regulating glycolysis/gluconeogenesis, pyruvate metabolism, lipid and atherosclerosis, Ras protein signal transduction and other biological processes.

     

/

返回文章
返回